-+ 0.00%
-+ 0.00%
-+ 0.00%

Sagimet Biosciences grants CEO David Happel 300,000 stock options, 300,000 performance-based RSUs

PUBT·06/03/2026 20:36:24
Listen to the news
Sagimet Biosciences grants CEO David Happel 300,000 stock options, 300,000 performance-based RSUs
  • Sagimet Biosciences granted equity awards on May 28, 2026 to CEO David Happel, CFO Thierry Chauche, chief legal and administrative officer Elizabeth Rozek.
  • Happel received 300,000 stock options, 300,000 performance-based restricted stock units; Chauche 50,000 of each; Rozek 100,000 of each.
  • Options carry a $7.27 exercise price, matching the May 28 closing price; vest in equal installments over 48 months.
  • PSUs pay out based on regulatory milestones; one-third vests on achievement determination, remainder over two annual installments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-070126), on June 03, 2026, and is solely responsible for the information contained therein.